Previous close | 202.20 |
Open | 201.00 |
Bid | 202.80 x N/A |
Ask | 203.20 x N/A |
Day's range | 199.90 - 203.15 |
52-week range | 166.30 - 203.15 |
Volume | |
Avg. volume | 248 |
Market cap | 132.061B |
Beta (5Y monthly) | 1.03 |
PE ratio (TTM) | 25.13 |
EPS (TTM) | 8.07 |
Earnings date | 25 July 2024 - 29 July 2024 |
Forward dividend & yield | 3.97 (1.96%) |
Ex-dividend date | 16 May 2024 |
1y target est | N/A |
The acquisition of CAES is set to bolster Honeywell's (HON) defense technology offerings across various domains, including land, sea, air and space.
This biotech stock surged after one of its gene therapies was approved by the Food and Drug Administration.
Honeywell International (HON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).